The drug alone also showed strong results, with 42% experiencing remission or mild OSA after one year
In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)
Enzyme activation - The highly reactive sulfide bond in glutathione wakes up or activates enzymes so that they carry out their function or are moved from one phase to the next
Compounded GLP-1 & GIP therapy leverages GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) working synergistically to enhance insulin secretion, reduce appetite, and promote fullness
Dont wait to take the next step toward better health
This cascade does four things relevant to muscle mass: it increases ribosomal protein synthesis, suppresses the muscle-atrophy transcription factors FoxO1 and FoxO3a, promotes satellite cell differentiation into new myofibers, and reduces autophagy-driven protein degradation
